- Home
- PCRX
as 11-05-2025 4:00pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.2B | IPO Year: | 2011 |
| Target Price: | $32.40 | AVG Volume (30 days): | 577.9K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.00 - $27.64 | Next Earning Date: | 11-06-2025 |
| Revenue: | $705,848,000 | Revenue Growth: | 2.25% |
| Revenue Growth (this year): | 7.27% | Revenue Growth (next year): | 10.18% |
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ceesay Abraham | PCRX | Director | Sep 4 '25 | Sell | $27.19 | 2,354 | $64,005.26 | 9,039 |
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
GlobeNewswire
7 days ago
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
Zacks
8 days ago
Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?
GlobeNewswire
9 days ago
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
GlobeNewswire
10 days ago
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
GlobeNewswire
a month ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Argus Research
4 months ago
PCRX: What does Argus have to say about PCRX?
Zacks
5 months ago
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Compare PCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.